Dr Margaret Chan
World Health Organization
Avenue Appia 20
1211 Geneva 27
Vienna, 24 December 2009
Dear Dr Chan,
it was on 28 June 1976 as I filed the first request with the Federal government of the Austrian Republic to examine the possibilities of the treating cancer patients with my drug UKRAIN.
UKRAIN (Australian Patent No. 2001 2094/01) has been produced from two approved substances, greater celandine alkaloids (European Pharmacopeia 6.0/1861) and thiotepa (U.S. Pharmacopeia & National Formulary USP 24 NF 19, p. 1651). This is the first anticancer agent accumulating mostly in cancer cells whereas its content in normal cells is substantially lower (http://www.ukrain.ua/enclosures/hohenwarter_1992.pdf). This has been also proven by means of auto fluorescence under UV-light (http://ukrain.ua/statti/004.htm, http://ukrain.ua/present/ukrain.html).
UKRAIN differently affects the oxygen consumption by malignant and normal cells (http://www.ukrin.com/docs/Brueller_1992). Moreover, this drug regenerates immune system (http://ukrain.ua/statti/017.htm). At therapeutic dose range UKRAIN only destroys cancer cells while normal cells remain undamaged. This was confirmed in a lot of studies from numerous research institutions, for example, Rochester University, USA (http://www.ncbi.nlm.nih.gov/pubmed/11062738). Therapeutic index (http://dictionary.reference.com/browse/therapeutic+index) of UKRAIN is 1250, on the contrary to standard anticancer drugs whose therapeutic index is 1.4 to maximal 1.8. The efficacy of UKRAIN in the treatment of malignant diseases has been confirmed in many clinical studies (http://www.ukrain.ua/enclosures/25_susak-1996.pdf, http://www.ukrain.ua/enclosures/24_bondar_1998.pdf, http://www.springerlink.com/content/rgu31qkawkbmmqfw/, http://www.ncbi.nlm.nih.gov/pubmed/17591092, http://ukrain.ua/statti/158.htm).
Prof. Peter Wodnianski, a famous Vienna dermatologist, 1984 was surprised by unexpectedly good results of the therapy with UKRAIN in a case of advanced malignant melanoma. He appealed to the Austrian government to study this promising medicine (http://www.ukrin.com/docs/wodniansky.pdf, http://www.ukrin.com/docs/wodniansky-eng.pdf). However, this appeal like many others appeals from physicians and researchers (http://www.ukrin.com/en/facts) have still been disregarded by Austrian government.
All this time a wall of silence has been established around UKRAIN. Thousands of people could not benefit from this drug. The book «Anticancer Pharmaceutical Ukrain - Criminal Story of a Prevention» by Eleonore Thun-Hohenstein (http://ukrin.com/en/book) describes how UKRAIN has been concealed. European Court of Human Rights communicated my application No. 34983/02 against the Republic of Austria and on 1 February 2005 delivered a judgment in my favour. (http://cmiskp.echr.coe.int/tkp197/view.asp?item=1&portal=hbkm&action=html&highlight=Nowicky&sessionid=40878743&skin=hudoc-en). Unfortunately, this did not change the Austrian government’s position regarding UKRAIN.
Ukrainian TV reporters were first who broke through this wall of silence in the program ‘Facts’ on 4 October 2009 at ICTV. They are going to continue their investigation to find out what is the reason to conceal UKRAIN.
After this broadcast we are often asked why this drug which saved many patients’ lives is unknown to wide public. To note is, for example, an advanced colon cancer patient with the life expectation of about six months. After the therapy with UKRAIN she is still alive, for 23 years now. (http://ukrin.com/en/colon) Another case is a patient with metastatic melanoma cured with UKRAIN (http://ukrin.com/en/warum-melanoma).
To clear all doubts on the therapeutic potency of UKRAIN multicentre randomised clinical trials according to GCP guidelines. As indication colorectal cancer can be chosen. Follow-up analysis of a previously performed study (http://www.ukrain.ua/enclosures/24_bondar_1998.pdf ) revealed 18 from 24 rectal cancer patients treated with UKRAIN 1998 are still alive (personal communication). These data will be presented at an international congress. Other possible indications are metastatic malignant melanoma or pancreatic cancer for the treatment of both cancers is still an unsolved problem. After such clinical trials will be completed, all doubts on therapeutic efficacy of UKRAIN will be definitively cleared and the patients all over the world will have access to this medicine. As all appeals of physicians and researchers have been disregarded by the government of Austria for more than 30 years, may I kindly ask you to initiate multicentre clinical trials with UKRAIN under your auspices.
Because this is a matter of public interest, I take the liberty of publishing this letter and your much-appreciated reply on the internet.
Dr. Wassil Nowicky